Fax: (410) 614-9335
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)†
Article first published online: 19 APR 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 22, pages 5601–5607, 15 November 2012
How to Cite
Nabors, L. B., Mikkelsen, T., Hegi, M. E., Ye, X., Batchelor, T., Lesser, G., Peereboom, D., Rosenfeld, M. R., Olsen, J., Brem, S., Fisher, J. D., Grossman, S. A. and for the New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium (2012), A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer, 118: 5601–5607. doi: 10.1002/cncr.27585
The trial was completed by the Adult Brain Tumor Consortium (previously the New Approaches to Brain Tumor Therapy [NABTT] Central Nervous System Consortium), the University of Alabama at Birmingham (Birmingham, AL), University Hospital and University of Lausanne (Lausanne, Switzerland), and the Cancer Therapy Evaluation Program (National Cancer Institute, Bethesda, MD).
- Issue published online: 30 OCT 2012
- Article first published online: 19 APR 2012
- Manuscript Accepted: 8 MAR 2012
- Manuscript Received: 14 FEB 2012
- 12Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481., .